The semaglutide revolution took its next leap forward on Wednesday: The Food and Drug Administration has approved Eli Lilly’s GLP-1 oral pill for sale in the United States.
The approval for the drug, which will be sold under the brand name Foundayo, marks an important technological inflection point for this class of drugs that is transforming obesity care in the US and around the world. The previous generation of GLP-1 treatments were injections: Patients (or their doctors) had to handle a needle and insert it into their body in order to reap the weight-loss benefits.
It’s hard to e...
HALO NEWSLETTER
Join HALO today and unlock this story instantly — It's Free
